You are here

Our science / Clinical Trials / Find a Trial / NCT01375127

Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients

Back to Search Print Save as PDF Bookmark Trial

NCT01375127

Last updated on February 20, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Los Angeles, California, 90024 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Kidney Transplantation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects have discontinued tofacitinib prior to the planned treatment duration in 2
completed Phase 2 studies; or have not enrolled in long-term extension studies.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- No other subjects are eligible for this study

NCT01375127
Pfizer
Completed
Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Graft Rejection, Kidney Failure, Kidney Transplantation
Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients
NCT00273871
All Genders
Kidney Transplantation
Study Investigating Rapamune For Post-Marketing Surveillance
NCT00484094
All Genders
13+
Years
Multiple Sites
Kidney Transplantation
Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
NCT00658359
All Genders
18+
Years
Multiple Sites
Kidney Transplantation
Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients
NCT00556257
All Genders

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now